fadfebrian/iStock via Getty Images Recent IPOs are driving securities lending revenues, with upcoming US listings likely to rebalance activity and support continued growth. Recent initial public offerings (IPOs) have played a notable role in shaping securities lending activity, with a small number of high-profile listings exerting a disproportionate influence on borrowing demand, fee levels and ov...
fadfebrian/iStock via Getty Images Recent IPOs are driving securities lending revenues, with upcoming US listings likely to rebalance activity and support continued growth. Recent initial public offerings (IPOs) have played a notable role in shaping securities lending activity, with a small number of high-profile listings exerting a disproportionate influence on borrowing demand, fee levels and overall revenue generation. The pattern observed over the past 12–18 months suggests that IPO-driven “specials” have become an increasingly important contributor to lending revenues, particularly where supply is constrained and positioning demand is elevated. Recent IPO Activity Among recent examples, CoreWeave ( CRWV ) stands out as a defining case. Following its 2025 listing, the stock generated substantial securities lending revenues, with approximately $759 million recorded in the last twelve months. Demand to borrow the stock intensified around key corporate events, including lock-up expirations, with borrowing fees rising sharply during periods of limited availability and strong investor positioning. This dynamic highlights how IPOs with limited free float and concentrated investor ownership can generate elevated fee environments, even if these conditions prove temporary. A similar, albeit less pronounced, effect has been observed in other IPOs such as Circle Internet Group Inc. ( CRCL ), along with additional new listings linked to digital assets, technology infrastructure, and energy transition themes. Market data indicates that several recent IPOs, including CoreWeave and Circle, ranked among the top U.S. equities by securities lending revenue during 2025, reflecting concentrated demand for short exposure or hedging activity. This clustering of revenue around a limited number of newly listed securities has reinforced the importance of event-driven opportunities in supporting lending income. In parallel, Asia-Pacific markets have emerged as a significant driver of glo...
PM Images/DigitalVision via Getty Images Market overview U.S. equities finished mixed to mostly lower in the first quarter of 2026, with the S&P 500 Index dropping 4.33%. Growth stocks broadly declined as highlighted by the Russell 1000 Growth Index's -9.78% return. Value and small-cap securities held up better, with the Russell 1000 Value Index gaining 2.10% and the Russell 2000 Index eking out a...
PM Images/DigitalVision via Getty Images Market overview U.S. equities finished mixed to mostly lower in the first quarter of 2026, with the S&P 500 Index dropping 4.33%. Growth stocks broadly declined as highlighted by the Russell 1000 Growth Index's -9.78% return. Value and small-cap securities held up better, with the Russell 1000 Value Index gaining 2.10% and the Russell 2000 Index eking out a positive 0.89% return. Markets moved higher to kick off the year, as continued economic resilience and strong corporate earnings outweighed geopolitical headlines around the U.S. ouster of Venezuela's president and President Trump's public desire to claim Greenland. Expectations for a continued strong economy and broadening earnings growth helped fuel a rotation into more cyclical and smaller-cap companies. Artificial intelligence (AI) remained in the spotlight, as its perceived potential to disrupt existing software companies weighed on these names. Additionally, there was ongoing focus on the Mag 7 stocks and the level of capital expenditures they were undertaking, with some market participants questioning the return on investment (ROI) of these investments. Top holdings (% of net assets) as of March 31, 2026 Verizon Communications 4.03 Constellation Brands 3.83 Epam Systems 3.78 Salesforce.com 3.64 American Tower 3.45 Freeport-McMoRan 3.45 Lowes Companies 3.32 CVS Health 3.18 Williams Companies 3.10 AES 3.04 Click to enlarge Top holdings exclude short-term holdings and cash, if applicable. Fund holdings are as of the date given, are subject to change at any time, and are not recommendations to buy or sell any security. Top five contributors - Effect on return (%) as of March 31, 2026 TechnipFMC 1.34 Corning 1.25 Verizon Communications 0.82 Chevron 0.80 Marathon Petroleum 0.78 Click to enlarge Top five detractors - Effect on return (%) as of March 31, 2026 Epam Systems -1.22 Salesforce.com -1.09 Wells Fargo -0.38 Centene -0.37 Qualcomm -0.37 Click to enlarge The major st...
Fines might be needed to deter travellers from grabbing hand luggage, says official from airlines body Iata Business live – latest updates Air passengers are increasingly putting lives at risk by filming emergencies and retrieving bags instead of evacuating planes, industry experts have said, with some suggesting fines could be needed. Passenger aircraft are designed to be fully evacuated in 90 se...
Fines might be needed to deter travellers from grabbing hand luggage, says official from airlines body Iata Business live – latest updates Air passengers are increasingly putting lives at risk by filming emergencies and retrieving bags instead of evacuating planes, industry experts have said, with some suggesting fines could be needed. Passenger aircraft are designed to be fully evacuated in 90 seconds in an emergency – but people reaching for hand luggage can significantly increase that time, blocking exits and aisles as well as damaging slides or causing injury. Continue reading...
File photo: Workers build piers for a high-speed rail transit bridge at a railway infrastructure construction site in Changsha, Hunan province. Photo: VCG China’s economic engine has long relied on local governments to spend their way to growth, but recent data suggests this machinery is stalling. The slowdown in fixed-asset investment in April 2026 is not merely a blip; it exposes a profound stru...
File photo: Workers build piers for a high-speed rail transit bridge at a railway infrastructure construction site in Changsha, Hunan province. Photo: VCG China’s economic engine has long relied on local governments to spend their way to growth, but recent data suggests this machinery is stalling. The slowdown in fixed-asset investment in April 2026 is not merely a blip; it exposes a profound structural shift in how local governments manage their finances, deploy capital and grapple with mounting debt. A closer look at local investment figures reveals a stark divergence. In April, fixed-asset investment growth across Chinese municipalities decelerated, with only a handful of regions — such as Beijing, Shanghai, Hubei and Xizang — managing to maintain positive momentum. The primary culprit is a sharp contraction in infrastructure spending, particularly in provinces burdened by heavy debt and sluggish revenue, such as Qinghai, Hunan and Tianjin.
Rescuers searched the rubble on Tuesday of a collapsed building in the southern Philippine city of General Santos, the worst hit by a powerful earthquake that has killed at least 37 people and injured hundreds, to reach two people still believed to be trapped inside. Regional fire officer Edgar Tanawan, who was leading the operation, said two people had been pulled out alive from the commercial b...
Rescuers searched the rubble on Tuesday of a collapsed building in the southern Philippine city of General Santos, the worst hit by a powerful earthquake that has killed at least 37 people and injured hundreds, to reach two people still believed to be trapped inside. Regional fire officer Edgar Tanawan, who was leading the operation, said two people had been pulled out alive from the commercial building, housing a grocery store and other businesses, but a third was found dead. Scanners had so...
Editor's note: Seeking Alpha is proud to welcome Income Retriever as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more » Kirpal Kooner/iStock via Getty Images Investment Thesis NexPoint Residential Trust ( NXRT ) is c...
Editor's note: Seeking Alpha is proud to welcome Income Retriever as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access. Click here to find out more » Kirpal Kooner/iStock via Getty Images Investment Thesis NexPoint Residential Trust ( NXRT ) is currently trading well below its peers with a discount of around 40% to the NAV and a P/FFO of around 9-10x. Recent management presentations on the REITweek 2026 continue to show a substantial gap between market price and underlying asset value, supporting the view of a persistent NAV discount. While the pipeline of new completions in Sunbelt will decrease starting from 2026 onwards, NXRT's focus on the Value-Add program continues to deliver double-digit returns for newly purchased properties or existing ones. At the same time, NXRT is a highly cyclical REIT, since the current supply in Sunbelt is high, as well as the interest costs. But at least the supply of new apartments is decreasing in a meaningful way from 2026 to 2028. Due to the fact that the company mainly relies on floating interest rates and their hedging expires this year, leasing spreads are increasingly under pressure. So, the valuation discounts reflect these upcoming structural risks, but they also indicate a significant rerating potential. Sector and Company Overview NXRT is, for me, one of the most interesting but also one of the riskiest stocks in the Sunbelt residential market. The company owns 36 Class B properties with 13,305 units in different regions like South Florida or Las Vegas. Supported by strong employment growth, migration trends, and the affordability advantage over Class A properties, NXRT's structural position in the Sunbelt remains intact, although there currently is a significant surplus of housing in the region. With an average rent of 1.485 USD per unit and 93.5% occupancy, the operati...
William Barton/iStock Editorial via Getty Images GSK ( GSK ) has agreed to acquire U.S. biopharmaceutical company Nuvalent ( NUVL ) in a deal valued at approximately $10.6B. Under the agreement, GSK will launch a tender offer within ten business days to acquire all outstanding Nuvalent Class A and Class B shares for $124 per share in cash, representing a 40% premium to Nuvalent's closing price on ...
William Barton/iStock Editorial via Getty Images GSK ( GSK ) has agreed to acquire U.S. biopharmaceutical company Nuvalent ( NUVL ) in a deal valued at approximately $10.6B. Under the agreement, GSK will launch a tender offer within ten business days to acquire all outstanding Nuvalent Class A and Class B shares for $124 per share in cash, representing a 40% premium to Nuvalent's closing price on Monday and a 26% premium to its 30-day volume-weighted average price. After accounting for Nuvalent's cash balance, GSK expects its net investment in the transaction to be approximately $9.4B (£7.1B). The acquisition adds three lung cancer assets to GSK's oncology pipeline, including late-stage investigational therapies zidesamtinib and neladalkib, which target ROS1- and ALK-positive non-small cell lung cancer (NSCLC), respectively. Both candidates are currently under FDA review, with potential U.S. approvals expected in 2026. GSK said the acquisition aligns with its strategy of acquiring companies with validated drug targets and therapies that address efficacy and tolerability limitations of existing treatments. The company expects the deal to be accretive to sales and core operating profit in 2027 and to core EPS by 2029, including anticipated synergies and portfolio optimization benefits. There is no change to GSK’s 2026 full-year guidance range of 7-9% core operating profit and core EPS growth. GSK will account for the transaction as a business combination. GSK will also assume Nuvalent’s existing revenue-sharing arrangements of low-single-digit royalties payable to Royalty Pharma and Deerfield. More on GSK, Nuvalent GSK plc (GSK) Presents at Jefferies Global Healthcare Conference 2026 Transcript GSK plc (GSK) Discusses Bepirovirsen Phase III Data and Advances in Hepatitis B Treatment Transcript GSK plc (GSK) Discusses Bepirovirsen Phase III Data and Advances in Hepatitis B Treatment - Slideshow GSK in talks to buy Nuvalent for over $9B - report Three studies used to ju...